We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatments for the Prevention and Management of Suicide.
- Authors
Kelly, Deanna L.; Gorelick, David A.; Wehring, Heidi J.; Vyas, Gopal; Buchanan, Robert W.
- Abstract
Clozapine, an antipsychotic medication, was approved by the U.S. Food and Drug Administration (FDA) for the indication of reducing the risk for recurrent suicidal behavior in persons with schizophrenia or schizoaffective disorder. We recommend that clozapine be considered for use in the treatment of this condition in persons with schizophrenia or schizoaffective disorder. 4 Buchanan RW, Kreyenbuhl J, Kelly DL, et al, Schizophrenia Patient Outcomes Research Team (PORT), The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements Schizophr Bull,, 2010, 36, 71-93, 19955390.
- Subjects
SUICIDE prevention; SCHIZOAFFECTIVE disorders
- Publication
Annals of Internal Medicine, 2020, Vol 172, Issue 2, p167
- ISSN
0003-4819
- Publication type
letter
- DOI
10.7326/L19-0706